Kumar Vinod, Kaur Prabhjot, Ayasolla Kameshwar, Jha Alok, Wiqas Amen, Vashistha Himanshu, Saleem Moin A, Popik Waldemar, Malhotra Ashwani, Gebeshuber Christoph A, Skorecki Karl, Singhal Pravin C
Department of Medicine and Feinstein Institute for Medical Research, Zucker School of Medicine, Hempstead, NY 11549, USA.
Department of Nephrology and Dermatology, Postgraduate Institute for Medical Research, Chandigarh 160012, India.
Biomolecules. 2024 Dec 10;14(12):1575. doi: 10.3390/biom14121575.
Patients carrying APOL1 risk alleles (G1 and G2) have a higher risk of developing Focal Segmental Glomerulosclerosis (FSGS); we hypothesized that escalated levels of miR193a contribute to kidney injury by activating renin-angiotensin system (RAS) in the APOL1 milieus. Differentiated podocytes (DPDs) stably expressing vector (V/DPD), G0 (G0/DPDs), G1 (G1/DPDs), and G2 (G2/DPDs) were evaluated for renin, Vitamin D receptor (VDR), and podocyte molecular markers (PDMMs, including WT1, Podocalyxin, Nephrin, and Cluster of Differentiation [CD]2 associated protein [AP]). G0/DPDs displayed attenuated renin but an enhanced expression of VDR and Wilms Tumor [WT]1, including other PDMMs; in contrast, G1/DPDs and G2/DPDs exhibited enhanced expression of renin but decreased expression of VDR and WT1, as well as other PDMMs (at both the protein and mRNA levels). G1/DPDs and G2/DPDs also showed increased mRNA expression for Angiotensinogen and Angiotensin II Type 1 (AT1R) and 2 (AT2R) receptors. Protein concentrations of Brain Acid-Soluble Protein [BASP]1, Enhancer of Zeste Homolog [EZH]2, Histone Deacetylase [HDAC]1, and Histone 3 Lysine27 trimethylated [H3K27me3] in WT1-IP (immunoprecipitated proteins with WT1 antibody) fractions were significantly higher in G0/DPDs vs. G1/DPD and G2/DPDs. Moreover, DPD-silenced BASP1 displayed an increased expression of renin. Notably, VDR agonist-treated DPDs showed escalated levels of VDR and a higher expression of PDMMs, but an attenuated expression of renin. Human Embryonic Kidney (HEK) cells transfected with increasing APOL1(G0) plasmid concentrations showed a corresponding reduction in renin mRNA expression. Bioinformatics studies predicted the miR193a target sites in the VDR 3'UTR (untranslated region), and the luciferase assay confirmed the predicted sites. As expected, podocytes transfected with miR193a plasmid displayed a reduced VDR and an enhanced expression of renin. Renal cortical section immunolabeling in miR193a transgenic (Tr) mice showed renin-expressing podocytes. Kidney tissue extracts from miR193aTr mice also showed reduced expression of VDR and PDMMs, but enhanced expression of Renin. Blood Ang II levels were higher in miR193aTr, APOLG1, and APOL1G1/G2 mice when compared to control mice. Based on these findings, miR193a regulates the activation of RAS and podocyte molecular markers through modulation of VDR and WT1 in the APOL1 milieu.
携带APOL1风险等位基因(G1和G2)的患者发生局灶节段性肾小球硬化(FSGS)的风险更高;我们推测,在APOL1环境中,miR193a水平升高通过激活肾素-血管紧张素系统(RAS)导致肾损伤。对稳定表达载体(V/DPD)、G0(G0/DPD)、G1(G1/DPD)和G2(G2/DPD)的分化足细胞(DPD)进行肾素、维生素D受体(VDR)和足细胞分子标志物(PDMM,包括WT1、足细胞表面蛋白、nephrin和分化簇[CD]2相关蛋白[AP])评估。G0/DPD表现出肾素表达减弱,但VDR和威尔姆斯瘤[WT]1以及其他PDMM的表达增强;相反,G1/DPD和G2/DPD表现出肾素表达增强,但VDR和WT1以及其他PDMM的表达降低(在蛋白质和mRNA水平均如此)。G1/DPD和G2/DPD的血管紧张素原和血管紧张素II 1型(AT1R)和2型(AT2R)受体的mRNA表达也增加。WT1免疫沉淀(用WT1抗体免疫沉淀的蛋白)组分中脑酸溶性蛋白[BASP]1、zeste同源物增强子[EZH]2组蛋白去乙酰化酶[HDAC]1和组蛋白3赖氨酸27三甲基化[H3K27me3]的蛋白浓度在G0/DPD中显著高于G1/DPD和G2/DPD。此外,BASP1沉默的DPD表现出肾素表达增加。值得注意的是,VDR激动剂处理的DPD表现出VDR水平升高和PDMM表达增加,但肾素表达减弱。用浓度递增的APOL1(G0)质粒转染的人胚肾(HEK)细胞显示肾素mRNA表达相应降低。生物信息学研究预测了VDR 3'非翻译区(UTR)中的miR193a靶位点,荧光素酶测定证实了预测位点。正如预期的那样,用miR19